Sotera Health (NASDAQ:SHC) Receives $15.70 Average Target Price from Analysts

Shares of Sotera Health (NASDAQ:SHC) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $15.70.

Several brokerages have issued reports on SHC. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research report on Tuesday, August 6th. Barclays raised their target price on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the completion of the sale, the director now owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 55.12% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SHC. Point72 DIFC Ltd boosted its holdings in Sotera Health by 556.6% in the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after acquiring an additional 5,544 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Sotera Health in the 2nd quarter worth $130,000. Brandes Investment Partners LP grew its position in Sotera Health by 301.3% in the 2nd quarter. Brandes Investment Partners LP now owns 56,429 shares of the company’s stock valued at $670,000 after purchasing an additional 42,367 shares during the period. Algert Global LLC bought a new stake in Sotera Health during the 2nd quarter valued at $169,000. Finally, Clearline Capital LP acquired a new position in Sotera Health during the second quarter worth $1,707,000. 91.03% of the stock is owned by institutional investors.

Sotera Health Stock Up 1.0 %

Shares of SHC opened at $16.76 on Wednesday. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of 88.21 and a beta of 2.07. The stock has a fifty day moving average of $15.24 and a 200-day moving average of $12.94.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The firm had revenue of $277.00 million for the quarter, compared to analyst estimates of $266.45 million. During the same period last year, the firm posted $0.19 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Sotera Health will post 0.64 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.